Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment
- 1 February 2000
- journal article
- review article
- Published by Elsevier in American Heart Journal
- Vol. 139 (2) , s38-s45
- https://doi.org/10.1067/mhj.2000.103742
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Platelet Glycoprotein IIb/IIIa AntagonistsCirculation, 1999
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- Heparin-Induced ThrombocytopeniaJournal of the American College of Cardiology, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- In-Laboratory Removal of Femoral Sheath Following Protamine Administration in Patients Having Intracoronary Stent ImplantationThe American Journal of Cardiology, 1997
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) TherapyCirculation, 1997
- Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery diseaseEuropean Heart Journal, 1996
- Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary InterventionCirculation, 1995
- Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.Circulation, 1994